目的 探討左西孟旦聯(lián)合曲美他嗪治療肺動(dòng)脈高壓（PH）患者的療效對(duì)心肌型脂肪酸結(jié)合蛋白（H-FABP）表達(dá)的影響。方法 采用回顧性、總結(jié)研究方法，選擇2016年1月-2018年2月在漯河市中醫(yī)院診治的PH患者101例作為研究對(duì)象，根據(jù)治療方法的不同分為觀察組51例與對(duì)照組50例，對(duì)照組給予曲美他嗪治療，觀察組給予左西孟旦聯(lián)合曲美他嗪治療，兩組都治療觀察1個(gè)月。比較兩組臨床療效、心功能指標(biāo)改善情況、肺動(dòng)脈收縮壓（PASP）及H-FABP變化情況。結(jié)果 治療后觀察組的總有效率為92.2%，對(duì)照組為72.0%，觀察組顯著優(yōu)于對(duì)照組（P<0.05）。治療后，觀察組患者左室收縮末徑（LVSD）、左室舒張末徑（LVDD）、左室射血分?jǐn)?shù)（LVEF）指標(biāo)均明顯改善，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；對(duì)照組患者治療后LVEF、LVSD指標(biāo)明顯改善，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，觀察組LVDD明顯高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組患者PASP均低于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組也低于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清H-FABP水平均明顯低于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組明顯低于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 左西孟旦聯(lián)合曲美他嗪治療PH能抑制H-FABP的釋放，降低PASP，促進(jìn)改善心功能，從而提高治療效果。

Objective To investigate the effects of levosimendan combined with trimetazidine on the expression of cardiac fatty acid binding protein (H-FABP) in patients with pulmonary hypertension (PH).Methods From January 2016 to February 2018,101 cases of PH patients treated in our hospital were selected and were divided into the 51 cases of experimental group and 50 cases of control group accorded to the different treatment methods.The control group were treated with trimetazidine,and the experimental group were given levosimendan combined with trimetazidine treatment.The changes of H-FABP were recorded.Results After treatment,the total effective rate of the experimental group were 92.2%,while that of the control group were 72%,the experimental group were better than the control group (P<0.05).After treatment,the LVEF,LVDD and LVSD in the experimental group compared before treatment were statistically significant (P<0.05),the comparison of LVEF and LVSD in the control group were statistically significant before and after treatment (P<0.05),and the difference of LVDD compared between the two groups after treatment were statistically significantly (P<0.05).After treatment,the systolic blood pressure (PASP) of the experimental group and the control group were lower than that before treatment (P<0.05),and the experimental group were also lower than that of the control group (P<0.05).After treatment,the serum H-FABP of the experimental group and the control group were lower than that before treatment (P<0.05),and the experimental group were lower than that of the control group (P<0.05).Conclusion Levosimendan combined with trimetazidine in the treatment of PH can inhibit the release of H-FABP,reduce PASP,and improve cardiac function,thereby improve the therapeutic effect.